Panagora Asset Management Inc. Purchases 567,249 Shares of Merck & Co., Inc. $MRK

Panagora Asset Management Inc. grew its position in shares of Merck & Co., Inc. (NYSE:MRK) by 410.5% during the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 705,442 shares of the company’s stock after buying an additional 567,249 shares during the quarter. Panagora Asset Management Inc.’s holdings in Merck & Co., Inc. were worth $74,255,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other hedge funds and other institutional investors have also recently modified their holdings of the company. Perryman Financial Advisory Inc. AD bought a new position in shares of Merck & Co., Inc. during the 4th quarter valued at $5,902,000. Palisade Asset Management LLC increased its stake in shares of Merck & Co., Inc. by 3.4% in the 4th quarter. Palisade Asset Management LLC now owns 35,284 shares of the company’s stock worth $3,714,000 after purchasing an additional 1,161 shares in the last quarter. Piedmont Capital Management LLC NC purchased a new stake in shares of Merck & Co., Inc. in the 4th quarter worth $476,000. Resources Management Corp CT ADV increased its stake in shares of Merck & Co., Inc. by 3,067.4% in the 4th quarter. Resources Management Corp CT ADV now owns 59,610 shares of the company’s stock worth $6,275,000 after purchasing an additional 57,728 shares in the last quarter. Finally, Seven Mile Advisory increased its stake in shares of Merck & Co., Inc. by 12.2% in the 4th quarter. Seven Mile Advisory now owns 7,512 shares of the company’s stock worth $791,000 after purchasing an additional 817 shares in the last quarter. 76.07% of the stock is owned by institutional investors.

Merck & Co., Inc. Trading Up 0.0%

Shares of MRK stock opened at $119.05 on Monday. Merck & Co., Inc. has a 52-week low of $76.66 and a 52-week high of $125.14. The company has a debt-to-equity ratio of 1.02, a quick ratio of 1.06 and a current ratio of 1.30. The firm has a market capitalization of $294.04 billion, a PE ratio of 33.54, a PEG ratio of 2.68 and a beta of 0.21. The stock has a fifty day simple moving average of $116.55 and a two-hundred day simple moving average of $113.32.

Merck & Co., Inc. (NYSE:MRK) last issued its quarterly earnings results on Thursday, April 30th. The company reported ($1.28) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($1.47) by $0.19. Merck & Co., Inc. had a return on equity of 27.55% and a net margin of 13.59%.The business had revenue of $16.29 billion during the quarter, compared to analyst estimates of $15.85 billion. During the same quarter in the prior year, the business posted $2.22 EPS. Merck & Co., Inc.’s revenue for the quarter was up 4.9% compared to the same quarter last year. Merck & Co., Inc. has set its FY 2026 guidance at 5.040-5.160 EPS. On average, analysts predict that Merck & Co., Inc. will post 5.17 EPS for the current fiscal year.

Merck & Co., Inc. Dividend Announcement

The firm also recently declared a quarterly dividend, which will be paid on Wednesday, July 8th. Shareholders of record on Monday, June 15th will be paid a $0.85 dividend. This represents a $3.40 dividend on an annualized basis and a yield of 2.9%. The ex-dividend date is Monday, June 15th. Merck & Co., Inc.’s dividend payout ratio is presently 95.77%.

Analyst Ratings Changes

Several equities research analysts have recently commented on MRK shares. Barclays started coverage on Merck & Co., Inc. in a research note on Friday, February 20th. They issued an “overweight” rating and a $140.00 price objective for the company. Royal Bank Of Canada restated an “outperform” rating and issued a $142.00 price objective on shares of Merck & Co., Inc. in a research note on Monday, March 30th. Citigroup started coverage on Merck & Co., Inc. in a research note on Wednesday, May 6th. They issued a “neutral” rating and a $125.00 price objective for the company. JPMorgan Chase & Co. upped their price objective on Merck & Co., Inc. from $125.00 to $135.00 and gave the stock an “overweight” rating in a research note on Monday, April 6th. Finally, Wall Street Zen upgraded Merck & Co., Inc. from a “hold” rating to a “buy” rating in a research note on Saturday, June 6th. One investment analyst has rated the stock with a Strong Buy rating, eleven have issued a Buy rating and seven have given a Hold rating to the company. According to data from MarketBeat.com, Merck & Co., Inc. has an average rating of “Moderate Buy” and a consensus target price of $128.18.

Trending Headlines about Merck & Co., Inc.

Here are the key news stories impacting Merck & Co., Inc. this week:

• Positive Sentiment: Merck Animal Health announced a definitive agreement to acquire TARGAN, a poultry biodevice company, which could strengthen Merck’s animal health division and broaden its technology-driven growth opportunities. Merck Animal Health to Acquire TARGAN
• Positive Sentiment: Merck saw unusually heavy call option buying, with traders purchasing 170,441 calls, a sharp jump versus normal volume that often signals bullish expectations from sophisticated investors.
• Positive Sentiment: Wells Fargo reiterated a buy rating on Merck, while another article highlighted that Wall Street’s overall bullish view continues to keep MRK on investors’ radar.
• Neutral Sentiment: Merck has also been featured in broader market commentary and “most searched” lists, suggesting rising attention rather than a new fundamental catalyst.
• Neutral Sentiment: One article noted Merck’s recent trading uptick but said it lagged the broader market, indicating modest price strength rather than a major breakout. Merck (MRK) Rises Yet Lags Behind Market: Some Facts Worth Knowing

Merck & Co., Inc. Profile

Merck & Co, Inc is a global biopharmaceutical company engaged in the discovery, development, manufacture and marketing of prescription medicines, vaccines, biologic therapies and animal health products. Its portfolio spans multiple therapeutic areas with a particular emphasis on oncology, vaccines and infectious disease, as well as therapies for metabolic and chronic conditions. Among its well-known products are the cancer immunotherapy Keytruda (pembrolizumab) and the human papillomavirus vaccine Gardasil; the company also markets a range of medicines and vaccines for veterinary use through Merck Animal Health.

Founded in the late 19th century as the U.S.